ReviewCellular & molecular immunology2012
Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.
Review in Cellular & molecular immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Cultivating Functional Natural Killer Cells from Mobilized Hematopoietic Stem Cells in Heavily Pretreated Hematologic Malignancies.International journal of molecular sciences · 2026Article
- Serum-free differentiation platform for the generation of B lymphocytes and natural killer cells from human CD34+ cord blood progenitors.Scientific reports · 2025Article
- State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens.International journal of molecular sciences · 2025Review
- Multiplexed iPSC platform for advanced NK cell immunotherapies.Cell reports. Medicine · 2025Review
- CAR NK cell therapy for solid tumors: potential and challenges.Antibody therapeutics · 2025Review
- Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy.Expert review of clinical immunology · 2024Review
- Genetic Manipulation Approaches to Enhance the Clinical Application of NK Cell-Based Immunotherapy.Stem cells translational medicine · 2024Review
- Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy.Cells · 2024Review
- Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.Molecular cancer · 2023Review
- Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells.Human cell · 2023Review
- Advancing cell-based cancer immunotherapy through stem cell engineering.Cell stem cell · 2023Review
- Role of Cytokines and Growth Factors in the Manufacturing of iPSC-Derived Allogeneic Cell Therapy Products.Biology · 2023Review
- Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model.Science advances · 2022Article
- Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs).International journal of molecular sciences · 2022Review
- Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.Journal of hematology & oncology · 2022Review
- Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges.Frontiers in immunology · 2022Review
- Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy.Immunotherapy advances · 2022Review
- Engineered NK Cells Against Cancer and Their Potential Applications Beyond.Frontiers in immunology · 2022Review
- Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma.World journal of gastrointestinal oncology · 2021Review
- Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors.Cancer immunology, immunotherapy : CII · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells are part of the innate immune system and are an alluring option for immunotherapy due to their ability to kill infected cells or cancer cells without prior sensitization. Throughout the past 20 years, different groups have been able to reproduce NK cell development in vitro, and NK cell ontogeny studies have provided the basis for the establishment of protocols to produce NK cells in vitro for immunotherapy. Here, we briefly discuss NK cell development and NK cell immunotherapy approaches. We review the factors needed for NK cell differentiation in vitro, which stem cell sources have been used, published protocols, challenges and future directions for Good Manufacturing Practice protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.